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Abstract 
Located on the short arm of chromosome 4, there exists a gene, IT15, responsible for the 
trinucleotide CAG expansion involved in the autosomal dominant neurodegenerative disorder 
known as Huntington’s disease (HD). The brain region associated with the most atrophy, the 
striatum, leads to expression of severe motor dysfunction, the hallmark feature of HD. To a 
lesser degree, the cortex and hippocampus show earlier deterioration indicative of the cognitive 
deficits that occur prior to motor symptom onset. The brain regions associated with HD-induced 
neuronal death additionally selectively express the protein Rhes - the combination of Rhes and 
mutant huntingtin being cytotoxic. Using a 3-nitropropionic acid animal model of HD, we 
hypothesized that animals with preserved prenylation of Rhes would display cognitive and motor 
symptomology similar to genetic models of HD while animals administered statins or 
bisphosphonates would show inhibited Rhes prenylation and delayed cognitive symptoms. 
Experimental animals, however, did not perform differently than control animals on shallow 
water variants of the t-maze and MWM.  
 
 
 
 
 
 
 
 
Huntington’s disease, Rhes, prenylation, statins, bisphosphonates, cognition
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Introduction 
Overview of Huntington’s Disease 
Neurodegeneration, the progressive loss of neuronal structure and function leading to 
cellular death, is a common characteristic of many debilitating diseases including Huntington’s 
disease (HD). This disorder produces deleterious effects in the motor, behavioral, and cognitive 
aspects of the affected individual’s life. Three hundred thousand Americans are currently 
affected by this disease, and an additional 200,000 are at-risk (Huntington’s Disease, 2012). This 
brain disorder was named after Dr. George Huntington following the dissemination of his 
thorough description of the hereditary ailment in 1872. In his article, “On Chorea,” he eloquently 
depicts the gradual nature of the disease as “…often occupying years in its development, until 
the hapless sufferer is but a quivering wreck of his former self.” Before much was known of the 
disease, Dr. Huntington described three components: it is hereditary, the symptomology does not 
manifest until adulthood, and it commonly begets suicide and insanity (Huntington, 1872).  
Huntington’s disease is an autosomal dominant brain disorder associated with an 
abnormally long trinucleotide CAG repeat (>36 repeats). Affiliates of the Venezuela 
Collaborative Huntington’s Disease Project, Gusella et al., (1983) mapped the mutation and 
localized it to chromosome 4. The Huntington’s Disease Collaborative Research Group (1993) 
later isolated the gene, IT15, containing the trinucleotide repeat responsible for the protein 
product, huntingtin, and its mutated form caused by codon expansion. Kieburtz et al. (1994) 
further identified a relationship between the number of CAG repeats and the age of HD onset. 
Due to the autosomal dominant nature of HD, those with an afflicted parent have a 50% chance 
of inheriting the mutation; therefore, these findings were essential for the early detection of the 
devastating disorder using genetic testing.  
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Huntington’s disease manifests as a symptom triad including motor, behavioral, and 
cognitive facets. Full symptomology is typically exhibited when the affected individual reaches 
adulthood, between 30 and 50 years of age. Motor symptoms include rigid or sporadic 
movements of the voluntary muscles of the face and extremities. This often leads to displays of 
unusual facial grimaces, chorea, dystonia, unsteady gait, lack of coordination, and difficulty with 
speech and swallowing. Following symptom onset, death typically occurs within 15 to 20 years. 
In 1888, J. Hoffman was the first to observe a juvenile form of the disease that developed from a 
family afflicted for three subsequent generations (Bates, 2005). In many genetically dominant 
disorders, the age of symptom onset decreases as the generations of inheritance increase, a term 
coined “anticipation.” Tidley, Frith, Crow, and Conneally (1988) found this to occur more 
frequently through the male line. Often subtle behavioral and cognitive changes will precede the 
more obvious motor symptoms and accompany progression of the disease. Early in the 
progression of disease, these may include irritability, apathy, anxiety, and depression; while 
thoughts of suicide, confusion, difficulty thinking, planning or organizing, memory loss, and 
dementia emerge later. Paulsen, Ready, Hamilton, Mega, and Cummings (2001) found that over 
50% of patients with HD showed symptoms of dysphoria, agitation, irritability, apathy, and 
anxiety while fewer than 12% displayed delusions, motor abnormalities, and hallucinations 
concurrently; however, 98% displayed at least one of these within a given month.  
Neuropathology  
 The neuropathological trademark feature of HD is the progressive neuronal degeneration 
that occurs within the striatum, the primary input structure of the basal ganglia comprised of the 
caudate nucleus, the putamen, and the nucleus accumbens. Imaging studies demonstrate the 
earliest and most robust changes occur in this area, displaying significant decreases in caudate 
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and putamen gray matter in a dorso-ventral gradient (Kassubek et al., 2004; Fennema-Notestine, 
et al., 2004; Kipps et al., 2005; and Douaud et al., 2006). Kipps et al. (2005) conducted a two 
year longitudinal study on patients with the mutant huntingtin gene who had not yet been 
diagnosed with HD. These patients exhibited early regional gray matter atrophy to the caudate, 
putamen, external segment of the globus pallidus, and the substantia nigra, all of which are 
targets of striatal projections. After diagnosis, however, patients showed overall volume 
reduction in pallidal nuclei, nucleus accumbens, thalamus, hippocampus, and hippocampal gyrus 
in addition to those regions already described by Kipps (Fennema-Notestine, 2004; Douaud, 
2006; Walker, 2007). Mounting evidence supports the idea that reduction is not limited to 
subcortical structures; there is a more widespread degeneration in the Huntington brain that also 
includes the cerebral cortex. Various studies using participants with HD show significant 
reductions in cortical grey and white matter volume as well as increased abnormal white matter 
signal, i.e. hyper intense white matter voxels falling in the range typical of grey matter (Halliday 
et al., 1998; Fennema-Notestine et al., 2004; Douaud et al., 2006; and Walker, 2007). The 
extension of abnormality, both structural and functional, was additionally correlated to 
increasing numbers of CAG polyglutamine codon repeats, striatal atrophy,  loss of GABAergic 
medium spiny neurons (MSNs), and hippocampal volume (Halliday et al., 1998; Fennema-
Notestine et al., 2004; Kassubek et al., 2004; and Kipps et al., 2005). Although generalized 
atrophy within the striatum occurs by a certain point in disease progression, research has shown 
differential susceptibility to neuronal degeneration between interneurons (<10%) and projection 
neurons (>90%) present in this area. The majority of striatal interneurons are relatively 
impervious to the progression of HD; however, the following four subpopulations of striatal 
projection neurons show gradual deterioration: striato-globus pallidus external (GPe), striato-
4 
 
substantia nigra pars reticulata (SNr), striato-globus pallidus internal (GPi), and striato-substantia 
nigra pars compacta (SNc) (Albin, 1995). Reiner et al. (1988) supported the notion that the 
striatal neuron projections descend relatively separately to the GP and SN terminals, with early 
and middle stages of HD showing a higher rate of degradation to those projecting to the GPe and 
SNr. As the disease progresses, projections to the GPi begin to display noticeable changes until 
the affected individual reaches the advanced stage where all classes are affected. Despite their 
names, the GPe and GPi are not homologous structures. The GPi and SNr, on the other hand, are 
embryologically and functionally homologous with one another and can be thought of as the 
same structure separated by the fibers of the internal capsule. Likewise, the SNr and SNc are not 
homologous structures. Names of basal ganglia nuclei were assigned on the basis of adjacency 
rather than functionality.  
Alexander, DeLong, and Strick (1986) introduced the basal ganglia-thalamocortical 
circuit model that demonstrated the pathway afferent neurons took as they descended from 
various cortical areas to the striatum, GP, and SN, and funneled through the thalamus to be 
redirected back to restricted areas of the cortex. The separate and diverse targets of the cortex, 
the basal ganglia output nuclei, and the thalamus suggested the existence of distinct parallel 
circuits, of which, Alexander and colleagues (1986) discovered five: two involving motor 
functions (motor and oculomotor circuit) and three involving non-motor functions (dorsolateral 
prefrontal [dlPFC], lateral orbitofrontal, and anterior cingulate circuit). This would indicate basal 
ganglia involvement in a diverse range of behaviors. Medium spiny neurons, the most vulnerable 
cells to HD degeneration, account for 90-95% of the striatal neuronal population, effectively 
explaining why this area of the brain is so drastically affected (Walker, 2007; Gil and Rego, 
2008). Following the basal ganglia-thalamocortical circuit model, cortical projections 
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predominantly target these GABAergic neurons, which in turn connect the striatum to output 
nuclei (Stocco, Lebiere, and Anderson, 2010).  
These networks described above can be delineated into two broad pathways which aid in 
sequencing motor systems: the direct pathway and the indirect pathway which oppose one 
another (Albin, Young, and Penney, 1989; DeLong, 1990). Only in the presence of dopamine do 
the basal ganglia-thalamocortical loops exert their functional effects on behavior. A clinical 
demonstration of this fact is the akinesia that results from progressive loss of dopaminergic 
neurons in Parkinson’s disease. The direct pathway, driven by dopaminergic stimulation of D1 
receptors, comprises inhibitory afferents to SNr and GPi output nuclei and results in subsequent 
disinhibition of the thalamocortical loop. The disinhibition of thalamic activity results in 
excitation of the cortex and resulting behavior. GABAergic striatal efferent neurons form the 
initial point in the indirect pathway. These neurons are inhibited by dopaminergic stimulation of 
D2 receptors, resulting in a net effect of disinhibition of the GPe and subthalamic nuclei. As a 
result, thalamic output to the cortex is inhibited. This signal is believed to inhibit all cortical 
activity except that within the target area (Albin, Young, and Penney, 1989; Stocco, Lebiere, and 
Anderson, 2010). The mutant huntingtin gene, however, produces detrimental effects within the 
indirect pathway circuitry. Without inhibition to control the surrounding cortical areas, the 
pathways become unbalanced, resulting in unintended and inappropriate motor and cognitive 
behavior (Albin, Young, and Penney, 1989). 
Cognitive Deficits in Humans 
The basal ganglia-thalamo-cortical loop is comprised of several parallel pathways that 
interconnect and communicate. Output from the striatal-thalamo portion of this system 
terminates in both motor and non-motor cortical regions, eliciting a variety of behavior. 
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Neuronal degeneration within this circuit can therefore drastically affect the Huntington disease-
diagnosed individual, impacting not only motor but cognitive function as well. It is currently 
inconclusive whether cognitive deficits originate from the degeneration of striato-cortical or 
cortico-striatal projections; however, both concepts have been implicated.  
Middleton and Strick (2000) suggest that basal ganglia output affects cognition, as 
pallidal and nigral projections to distinct cortical regions, in particular to the dlPFC, contribute 
greatly to the heterogeneity of HD symptomology in the cognitive and affective domains. As 
previously mentioned, the striatum degenerates in a dorso-ventral gradient, indicating that 
projections from the dorsal striatum are amongst the first to degenerate. As neurons projecting 
from the dorsal striatum to the dlPFC die, spatial working memory becomes impaired, a 
phenomena relating to the “Where” functioning attributed to the dorsal cortex (Lawrence et al., 
1996; Brandt et al., 2005). Spatial span length in addition to pattern and spatial recognition 
memory are also affected by the degeneration of the striato-frontal pathway (Lawrence et al., 
1998). A large portion of the basal ganglia output nuclei communicates specifically with the 
dlPFC, the cortical region associated with learning and planning new sequences; however, nine 
other cortical areas have been implicated as targets of non-motor signal transmission within the 
basal ganglia-thalamo-cortical circuit (Middleton and Strick, 2000). Imaging studies have shown 
striatal metabolism to be positively related to verbal learning memory and the Performance 
Intelligence Quotient,  measures that are diminished in patients with HD (Berent et al., 1988). 
Furthermore, subcortical thalamic nuclei relaying information between the striatum and 
prefrontal cortex exhibit substantial volume loss that co-varies with cognitive performance, 
contributing to deficits in psychomotor speed and executive functioning (Kassubek, Juengling, 
Ecker, and Landwehrmeyer, 2005).  
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Cognitive impairment is often exhibited before clinical diagnosis and increases in 
severity while nearing motor symptom onset (delineated by number of CAG repeats) (Lawrence 
et al., 1998; Duff et al., 2010; O’Rourke et al., 2011; and Stout et al., 2011). Duff et al. (2010) 
utilized the Mild Cognitive Impairment assessment to evaluate individuals with HD on the 
following cognitive measures: attention, verbal fluency, psychomotor speed, executive 
functioning, memory, and visuospatial functioning. Approximately 40% of the participants in the 
prodromal stage of HD scored below 1.5 standard deviations on at least one of these cognitive 
domains, rates of which doubled for those closer to symptom onset. Significant deterioration of 
the cortical ribbon, particularly pyramidal cells in layers III, V, and VI of the dlPFC, transpires 
early and presents differently throughout the progression of HD (Sieradzan and Mann, 2001; 
Rosas et al., 2002). Consistent with previous studies, this regional degeneration was associated 
with impaired learning and planning new sequences.  
The frontal lobe has been implicated with preclinical cognitive deficits in numerous 
studies of HD. Deficits in psychomotor speed, verbal memory, executive function, cognitive 
flexibility, working memory, visual search, sustained attention, and visuoperceptual ability are 
reported prior to overt symptoms presented in patients with HD (Rosenberg, Sorensen, and 
Christensen, 1995; Hahn-Barma et al., 1998; Brandt et al., 2008; O’Rourke et al., 2011; and 
Stout et al., 2011). Degeneration to the fronto-striatal pathway could explain why these effects 
are seen before the more obvious motor impairments occur; however, conclusions should be 
carefully weighed as others have found little evidence for the existence of prodromal frontal lobe 
deficits in the asymptomatic stage of HD (Blackmore, Simpson, and Crawford, 1995; Rosas et 
al., 2002). 
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As HD progresses into the mild and moderate stages, global cognitive impairments 
continue to be displayed in executive function, visuospatial skill, episodic memory, verbal 
fluency, psychomotor speed and reasoning, spatial planning, selective attention, and recall and 
recognition memory (Paulsen, 1995; Backman, 1997; Montoya, 2006; and Rosas et al., 2008).  
There is mounting evidence of significant frontal lobe involvement, which supports the notion 
that there may exist a fronto-striatal dementia (Backman et al., 1997). Hodges, Salmon, and 
Butters (1990) show that advanced stage exacerbates dementia as impairments in information 
encoding, storage, and retrieval become severe. These deficits have great repercussions on both 
short- and long-term memory. 
Mouse Model 
Similar to humans living with HD, longer CAG expansions in animal models are related 
to the onset and progression of the disease on several fronts: reductions in grey and white matter, 
cortical thickness, and regional atrophy (Lafore et al., 2001; Sawiak, Wood, Carpenter, and 
Morton, 2012). Within a rat model of HD, Fusco et al. (1999) found huntingtin protein and 
mRNA to be abundant not only in the vast majority of striatal neurons, but in corticostriatal 
neurons as well. Accumulation of mutant huntingtin in the cortical neurons further predicted 
onset and severity of symptoms as striatal neuronal responses were altered following cortical 
stimulation (Laforet et al., 2001).  These results suggest that corticostriatal neurons with the 
mutant protein may hold a destructive role towards their downstream striatal neurons. Miller, 
Walker, Barton, and Rebec (2011) studied symptomatic HD animal models and found altered 
corticostriatal disruptions, especially during tasks which stimulated synaptic plasticity. While 
there was no clear trend in corticostriatal dysfunction and HD progression, it can be reasonably 
hypothesized that such disturbances occurred during the asymptomatic phase and continued 
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throughout HD advancement. Comparable to findings in preclinical HD human studies, animal 
models consistently show cognitive impairments that occur before motor symptom onset and 
progress throughout the course of the disease (Lione et al., 1999; Murphy et al., 2000; Mazarakis 
et al., 2005; Van Raamsdonk et al., 2005; Cummings et al., 2006; Cummings et al., 2009; and 
Giralt et al., 2011). Early cognitive deficits often lead to a more global impairment in cognition. 
Procedural learning, working memory, executive function, impaired recognition memory, 
sensorimotor gating, and strategy shifting, all of which are impaired in patients with HD, were 
each found deficient in a mouse model of HD prior to motor symptom onset and progressed to 
more global cognition deficits (Van Raamsdonk et al., 2005; and Cummings et al., 2006).  
Additionally, performance on tasks sensitive to frontostriatal and hippocampal function, such as 
the Morris water maze (MWM), visual cliff avoidance, two-choice swim tank, and the T-maze, 
was gradually impaired during HD progression (Lione et al., 1999). Changes in synaptic 
plasticity in the hippocampal and perirhinal cortex, areas involved in spatial and recognition 
memory, were further displayed (Murphy et al., 2000; Cummings et al., 2006; and Ransome, 
Renoir, and Hannan, 2012). Overall, altered communication throughout the cortical pyramidal 
neurons involving both inhibitory and excitatory inputs plays a role in the development and 
progression of the disease (Cummings et al., 2009). 
3-nitropropionic acid model.  3-nitropropionic acid (3NP) is a naturally occurring 
mitochondrial toxin present in both plants (Indigofera endecapylla) and fungi (Aspergillus 
flavus). Its toxic effects are exerted by the suicide inhibitor of succinate dehydrogenase which 
leads to an irreversible blockade of the Krebs cycle (Alston, Mela, and Bright, 1977). Ingestion 
of the toxin has been the cause of widespread loss of cattle in the United States, and it is directly 
related to the moldy sugarcane food poisoning epidemic in China. Among survivors, 
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gastrointestinal disturbance, encephalopathy, coma, dystonia, and chorieform movements were 
documented in addition to the development of putamen cell death (Liu, Luo, and Hu, 1992; 
Ludolph et al., 1991). Since the discoveries of 3NP, it has become a prevalent model in the 
research surrounding HD.  
Ludolph et al. (1991) conducted an extensive review on the history of 3NP and animal 
studies that exemplified reports of lesioning in the basal ganglia, primarily the striatum, 
thalamus, hippocampus, spinal tracts, and peripheral nerves. Further evidence was supported by 
Hamilton and Gould (1987) when they found rats treated with 3NP to develop symmetrical 
bilateral lesions in the striatum, hippocampus, dentate gyrus, and thalamus. The caudate-putamen 
(CPu) was affected in all animals, while damage to other structures never occurred alone. Dosing 
regimens vary widely in the literature; however, it is relatively consistent that subacute 3NP 
treatment results in broad bilateral neuronal loss to the striatum and hippocampus whereas 
chronic 3NP treatment results in a more selective dorsolateral striatal lesion (Beal et al., 1993; 
Guyot et al., 1997). The cortex is relatively preserved except in animals displaying the most 
severe injury. In these cases, the integrity of cortical tissue laterally surrounding the CPu and 
rhinal sulcus becomes compromised (Hamilton and Gould, 1987). Furthermore, Chyi and Chang 
(1999) findings of signal intensity increases in the rat striatum and hippocampus but not the 
cortex is consistent with the literature on lesioning data. Blum et al. (2003), on the other hand, 
found lowered succinate dehydrogenase action in both the striatum and outer layers of the cortex, 
indicating 3NP involvement in both.  
Apart from the typical movement dysfunction apparent in 3NP literature, exposure 
produces cognitive dysfunction. Baboons receiving chronic 3NP showed both spontaneous 
abnormal movements and significant impairment on the object retrieval detour task. This is a 
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task sensitive to frontostriatal circuitry, yet lesions were found exclusively in the bilateral 
striatum with sparing to the cortex and prefrontal cortex (Palif et al., 1996). Mehrotra and 
Sandhir (2014) found deficits in both motor coordination and performance of a T-maze in rats 
sub-chronically treated with 3NP. And finally, rats both acutely and chronically treated with 3NP 
showed impaired memory on the MWM in addition to abnormal walking patterns (Duckworth et 
al., 1999; Teunissen et al., 2001). These results are consistent with the 3NP lesioning literature as 
tasks targeting the striatum (T-maze) and hippocampus (MWM) are those that are affected 
alongside motor abnormalities.  
Role of Rhes 
The Ras homolog enriched in the striatum (Rhes) is a gene that encodes a small guanine 
nucleotide (GTP)-binding protein within the brain (Falk et al., 1999). The mRNA and protein 
product (Rhes) are predominantly expressed in the striatum, with lesser expressions localized to 
several other brain regions. Amongst them include the nucleus accumbens or ventral striatum, 
and to a lesser degree, cortical layers II/ III and V, hippocampal pyramidal and granular layers, 
the dentate gyrus, the piriform cortex, anterior thalamic nuclei, the olfactory tubercle, the inferior 
colliculus, and the cerebellar granular layer (Spano et al., 2004; Vargiu et al, 2004; and Harrison, 
LaHoste, and Ruskin, 2008). As identified by Harrison, LaHoste, and Ruskin (2008), Rhes 
mRNA expresses itself in different brain structures in a developmental pattern. The first strong 
detection occurs early in development in the anterior thalamic nuclei, hippocampus, and 
cerebellum, followed in superficial cortical layers then in the striatum mid-to-late development. 
The most notable expression by adulthood, however, is within the CPu and the shell of the 
nucleus accumbens (Harrison and LaHoste, 2006).  
12 
 
The pattern in which Rhes mRNA manifests closely resembles the pattern of neuronal 
degeneration and symptomology found in patients with HD. This would suggest a potential 
Rhes-mutant huntingtin (mHtt) interaction supporting the HD neuropathology. Subramaniam, 
Sixt, Barrow, and Snyder (2009) used this theory to answer the following questions: 1) Does 
Rhes bind to the Htt protein, 2) Does Rhes influence mHtt cytotoxicity, 3) How may Rhes 
facilitate mHtt cytotoxicity, and 4) Does Rhes influence mHtt aggregation? The authors found 
overexpressed Rhes bound vigorously with the mHtt protein reducing cell survival by 50%; 
however, cell survival was not decreased when Rhes was expressed alone, when mHtt was 
expressed alone, or when wild-type huntingtin (wtHtt) was expressed with Rhes. Interestingly, 
mHtt, not wtHtt, forms aggregates that are reduced in the presence of Rhes overexpression, 
increasing the cytoplasmic levels of mHtt and eliciting neurotoxicity. In other words, when Rhes 
binds to the mHtt protein, SUMOylation (the attachment of a small ubiquitin-like modifier, 
SUMO, to a protein) occurs leading to a cytotoxic disaggregated soluble product (Steffan et al., 
2004). In support, Rhes knock-out (KO) mouse models significantly delayed cortical and striatal 
neurodegeneration, symptom onset, and dysfunction (Baiamonte et al., 2013; Mealer, 
Subramanian, and Snyder, 2013). Furthermore, Spano et al. (2004) observed no cognitive 
impairment amongst Rhes KO mice, an observation that alludes to the Rhes protein’s 
involvement in learning and memory processes outside of its involvement in the striatum. In 
relation to the 3NP model, Mealer, Subramaniam, and Snyder (2013) replicated the findings that 
Rhes knockout mice performed better on motor tasks and displayed less dorsolateral striatal 
neurodegeneration using an acute dosage regimen of 3NP.  
Relation to the mevalonate pathway.  Common to all complex eukaryotes and several 
bacteria, the mevalonate pathway, or 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-
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CoA reductase) pathway, is an important cellular metabolic pathway involved in converting 
mevalonate into cholesterol, steroid hormones, lipoproteins, and hydrophobic molecules that 
post-translationally modify cellular signaling (Buhaescu and Izzedine, 2007). These molecules 
additionally aid in cell membrane maintenance, protein anchoring, and protein prenylation.  
Figure 1 depicts two enzymatic targets for drugs that inhibit Rhes prenylation via the 
mevalonate pathway. The most upstream target, HMG-CoA reductase, converts HMG-CoA to 
mevalonate. Statins are well-known HMG-CoA reductase inhibitors and act to suppress the 
entire mevalonate pathway (Buhaescu and Izzedine, 2007; Sadowitz, Maier, and Gahtan, 2010). 
In particular, they prevent synthesis of isoprenoid intermediates necessary for lipid attachment 
posttranslational modification of proteins, i.e. Ras-like proteins (Liao and Laufs, 2005). A target 
downstream mevalonate, farnesyl diphosphate synthase (farnesyl PP synthase), converts geranyl 
diphosphate (geranyl PP) to farnesyl diphosphate (farnesyl PP). Bisphosphonates are widely 
accepted inhibitors of farnesyl PP synthase and therefore can block the downstream prenylation 
of Rhes (Dunford et al., 2001). Vincenzi et al. (2003) took these a step further and hypothesized 
that statins might potentiate bisphosphonate activity on the mevalonate pathway. Based on these 
findings, we decided to use a lipophilic statin, simvastatin (Sim), and a potent nitrogenous 
bisphosphonate, zoledronic acid (ZolA), alone and combined to investigate the upstream, 
downstream, and combined effects drug treatment targeting enzymes to inhibit Rhes prenylation 
would have on mouse behavior.  
 Figure 1.  Inhibition of Rhes Prenylation via the Mevalonate Pathway
Note: HMG-CoA reductase: 3-hydroxyl
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-3-methylglutaryl-Co-enzyme A; BPP: bisphosphonates; 
and PP: diphosphates. 
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Hypotheses 
The purpose of this study was to test hypotheses regarding the role of Rhes in mediating 
cognitive dysfunction in a 3NP model of HD.  The basis of the hypotheses are provided by two 
facts: Rhes is a necessary co-factor in the neuronal and behavioral toxicity induced by mutant 
huntingtin protein or by 3NP; and for its effects to occur Rhes must be prenylated, allowing for 
its anchorage in the inner surface of the cell membrane.  From these two observations we argue 
that administration of drugs that inhibit prenylation, and thereby decrease the bioactivity of Rhes, 
will exert a protective effect on the cognitive dysfunction induced by 3NP.  We tested the 
following specific hypotheses: 
 
Hypothesis 1 – Administration of 3NP to mice will impair learning in tasks that require 
normal functioning of the striatum or hippocampus. 
 
Hypothesis 2 – Pharmacological inhibition of HMG-CoA reductase by administration of 
a statin (simvastatin) will be protective against the toxic effects of 3NP on cognition. 
 
Hypothesis 3 – Pharmacological inhibition of farnesyl diphosphate synthase by 
administration of a nitrogenous bisphosphonate (zoledronic acid) will be protective 
against the toxic effects of 3NP on cognition. 
 
Hypothesis 4 – Combined administration of a statin and a bisphosphonate will be most 
protective against the toxic effects of 3NP on cognition. 
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Method 
 The methods used were designed to measure cognitive dysfunction as the result of striatal 
damage. Motor dysfunction is the hallmark symptom of diseases involving striatal degeneration, 
amongst them, Huntington’s disease; therefore, it was no surprise that the development of 
cognitive abnormalities in human HD has been overshadowed by the more obvious motor 
symptoms. However, the striatum receives extensive input from the entire cerebral cortex and 
ultimately directs output to the prefrontal lobe, an area known to be critical for cognition. 
Cognitive symptoms are known to develop prior to the appearance of motor symptoms, and we 
hoped to elucidate these findings using 3-nitroproprionic acid (3NP) to selectively disintegrate 
striatal neurons in mice and emulate a model of HD. We were additionally interested to see if 
drug treatment targeting Rhes prenylation would affect cognitive performance in 3NP treated 
mice.  
Animals 
Eighty-two male albino Hsd:ICR (CD-1) mice weighing ~30g on arrival were purchased 
from Harlan Laboratories (Indianapolis, IN). Mice were housed in groups of five under 
controlled conditions of temperature and humidity, on a normal 12:12 hour light:dark cycle 
(lights on 0700). Access to food and water was ad libitum. Body weight was recorded daily. 
Animals were housed and handled in strict accordance with the regulations of the U.S. Public 
Health Service; all conditions and procedures were approved by the University of New Orleans 
Institutional Animal Care and Use Committee.  
Procedure 
Drug administration.  All drugs were dissolved to the chosen concentrations in sterile 
phosphate buffered saline (0.1 M PBS) and administered intraperitoneally (i.p.), 10 ml/kg body 
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weight. 3-Nitroproprionic acid (3NP), a striatal-selective neurotoxin, was dissolved to a 
concentration of 7.7 mg/ml, then neutralized to pH 7.4 with 10 N sodium hydroxide (NaOH; 
1:100) (Mealer et al., 2013) yielding a final concentration of 77 mg/10 ml. Since dosage of 3NP 
varies with day, volume of injectate was adjusted so as to administer the correct dosage for a 
given animal. Futhermore, we were constrained by the fact that treatment drugs needed to be 
given for several days (based on the estimated half-life of Rhes) in order to exert their 
therapeutic effects and to allow ZolA access to the brain made possible by the disruption of the 
blood-brain barrier (BBB) caused by 3NP (Duran-Vilaregut et al., 2009). Based on previous 
studies and these constraints, we adopted the following 3NP regimen. Mice were injected once 
per day for 7 days using an escalating regimen. The starting dose was 50 mg/kg body weight and 
increased by 15% each day, yielding rounded numbers of 50, 58, 66, 77, 89, 102, and 118 mg/kg. 
The cumulative dose was 560 mg/kg (Stefanova et al., 2005).   
The statin simvastatin (Sim), and the nitrogenous bisphosphonate zoledronic acid (ZolA) 
inhibit different enzymes at various points along the mevalonate pathway, ultimately decreasing 
protein farnesylation. ZolA (1.0 or 0.5 mg/kg) and Sim (40 mg/kg) were diluted in sterile 0.1 M 
PBS and given as 10 ml/kg. Mice were randomly assigned to receive these drug treatments 
(Table 1) over the seven day course of injections.  
Because of a general toxic effect observed in mice in some drug conditions (40 of 82 
animals died prematurely- see Results), drug treatment was terminated prior to the injections of 
Day 6 and behavior was recorded. We then added mice to the 3NP/Sal group (n = 7). In addition, 
two new drug treatment groups were added. In both, the dose of ZolA was cut by half (0.5 
mg/kg) and administered together with Sim/3NP (n = 9) or Sim/Sal (n = 6). 
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Table 1  
Drug Treatment Groups 
Squad Toxin Drug Tx Sample Size 
1 Sal Sal 12 
2 3NP Sal 12 
3 3NP Simvastatin 19 
4 3NP Zoledronate, 1 mg/kg 12 
5 3NP Simvastatin + Zoledronate, 1 mg/kg 12 
6 3NP Simvastatin + Zoledronate, .5 mg/kg 9 
7 Sal Simvastatin + Zoledronate, .5 mg/kg 6 
Total        82 
 
Cognitive behavioral tasks.  To determine whether our 3NP mouse model of HD 
developed the same cognitive dysfunction as observed in genetically modified mice with the HD 
alleles and patients with HD, we used the battery of tests described below. We chose these tests 
within the context of the brain structures that mediate the behavior required to successfully 
perform the task. 
Apparatus.  Modeled after the Oxford paddling pools (Deacon, 2013), the octagonal 
behavioral apparatus (45.72 cm diameter) was made of clear Lexan and contained eight exit 
holes (5.08 cm diameter) located medially on each wall face (20.32 x 26.67 cm) 3 cm from the 
floor. The floor was covered with water (20 - 22 C) 2 cm deep. The water was deep enough to 
act as an aversive stimulus, but not deep enough to require swimming. The apparatus was used in 
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this open-field like structure for the shallow water variant of the MWM; however, a few 
modifications were necessary for use in the T-maze.  
T-maze.  In order to assess striatal mediated habit learning, Lexan walls (painted black to 
reduce visual cues) were inserted into the center of the maze to create a three-armed enclosure in 
the shape of a “T” (arms: 20.32 x 5.08 x 22.86 cm). The start arm and one of the side arms 
terminated with a false exit (i.e. the escape arm was blocked), and the remaining arm ended with 
a true exit connected to a black escape tube (30.48 cm long). Mice were placed in a heated cage 
after having found the true exit. Following counterbalancing and randomization, left and right 
true exits were pre-assigned to each mouse and designated for escape throughout experimental 
testing.  
Habituation.  Two black walls were extended from the south to north exits to create an 
enclosed straight path. Mice were placed at the south end and given two 60 second trials to 
escape through the exit tube located at the north end.  
Striatal mediated habit learning.  Methodology is based on that used by Guariglia and 
Chadman (2013). Mice were given 20 trials on the sixth day prior to injections to find the left or 
right exit pre-assigned to them. In the first five trials, the start arm was located south with the 
east and west arms serving as either true or false exits. By doing this, we were able to establish 
either a left or a right body turn necessary for exit per mouse, forcing mice to use an egocentric, 
striatally-mediated strategy. During the remaining 15 trials, the three armed enclosure was 
continuously rotated counterclockwise on the N/S/E/W cardinal axis moving the start arm from 
the south to the east, north, west, and south again. By doing this, we were able to remove the 
potential for guidance by spatial cues and ensure a habit was formed through body turns. Mice 
were allotted 60 seconds per trial and were given a rest period in a heated cage following escape. 
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If they could not find the exit, mice were manually guided to it. Entrances into the false arm or 
failure to move past the start arm were counted as errors. If a mouse found the true exit by initial 
body turn, it received a score of 0; if a mouse made any errors, it received a score of 1. The 
maximum number of errors per mouse was 20.    
Morris water maze.  This task modeled after the Oxford water paddling pool task 
(Deacon, 2013) was utilized to assess allocentric spatial learning mediated by the hippocampus. 
Of the eight exit holes, seven were plugged with a plastic stopper. The remaining true exit was 
attached to a black tube for escape from the aversive open water field. Mice were placed into a 
heated cage after finding the true exit. Visually stimulating cues (horizontal, vertical, right 
diagonal, and left diagonal stripes) were adhered to the north, south, east, and west walls of the 
maze to aid in spatial navigation. To reduce the potential for cue preference, true exits were only 
assigned to the walls of the maze that did not contain visual stimuli (northwest, northeast, 
southwest, and southeast). Following careful counterbalancing and randomization, these four 
cardinal directions were pre-assigned to each mouse and designated for escape throughout 
experimental testing. 
Hippocampal mediated learning.  Methods for acquisition were modeled after those used 
by Pettan-Brewer and colleagues (2013). On the sixth day prior to injections, mice were given 
eight trials to navigate to the pre-assigned exit hole using spatial landmarks. Mice were lowered 
by the base of their tails into the center of the apparatus and allotted 60 seconds to find the 
escape. If they could not find the exit in that time frame, they were manually guided to it. 
Following escape, mice were placed on a platform above the water and in front of their deemed 
exit tube for 30 seconds. This gave them time to notice their surroundings in relation to their 
escape hole. Each was given an inter-trial rest period in a heated cage following escape and 
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platform time. If a mouse approached a false exit within heads distance and touched it with its 
nose or forepaw, it was charged with an error. Mice failing to find the exit within 60s were 
assigned the ceiling 7 errors/trial (Deacon, 2013). The maximum number of errors per mouse 
was 56.  
Results 
We utilized a 3NP model for HD to test whether drug treatment targeting the 
farnesylation of Rhes would alleviate striatally- and hippocampally-mediated cognitive decline 
as measured by subjects’ performance in a shallow water variant of a T-Maze and a MWM. 
Before analyzing the data, we examined our independent variables,  Drug Treatment group and 
Number of treatment Injections, and our dependent variables: T-Maze: Amount of Time to 
complete the task and Task Performance, and MWM: Task Performance and Health (healthy 
(=1), sickly (=2), or dead (=3)) for theoretical and practical issues that may limit our planned 
analyses of covariance. The sample included 82 animals, of which 40 subjects were missing data 
at all measures and omitted from analysis. Due to the high sickness and mortality rate, we 
conducted analyses on the health of the animals to investigate a toxicity issue. We further 
screened the variables to evaluate assumptions of normality, homogeneity of variance, linearity, 
multicolinearity, and homogeneity of regression. 
Animal health and drug toxicity 
Data were analyzed with analyses of covariance (ANCOVA) in order to investigate 
whether Health of the animals (dependent variable: healthy, sickly, or dead) was affected by their 
placement in Drug Treatment groups (independent variable: Table 1) while controlling for the 
Number of treatment Injections (covariate). Scatter plot and Pearson correlation suggested that 
Health (dependent variable) and Number of treatment Injections (covariate) were not linearly 
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related (p = .250); therefore, we decided to conduct a one way analysis of variance (ANOVA) to 
test whether Health (dependent variable) varied across different Drug Treatment groups 
(independent variable). 
One subject was removed from analysis due to a death caused by experimenter error 
rather than ‘natural’ means. There were no outliers or signs of abnormal kurtosis and skew; 
however, Levene’s test was significant (p < .001). We therefore could not assume homogeneity 
of variance and conducted Dunnett C post hoc tests to determine where among Drug Treatment 
groups differences in Health existed. Results indicated significant variation in Health amongst 
the different Drug Treatment groups [F(6, 74) = 13.492, p < .001]. Table 2 presents the means, 
standard deviations, and sample size (n) for each group.  
When the means are ordered from low to high mortality, two homogenous subsets 
emerge with one overlapping mean.  There are no significant difference between Sal/Sal and 
either of the groups in which ZolA was given at a dose of 0.5 mg/kg, even when 3NP was 
included.  Based on homogeneity, these are the “healthy” groups.  The group given 3NP in 
addition to Sim is not significantly different from any other group, indicating a “sickly” group, 
not healthy, but not close to death. Likewise, the group given 3NP alone was significantly more 
sickly than the two “healthy” groups administered drugs in combination with Sal but were 
significantly healthier than the sickest group, 3NP/Sim+1ZolA. A second homogenous group, 
3NP-treated animals that were given Sim or ZolA at a dose of 1 mg/kg either alone or in 
combination constitutes the sickest subset, significantly worse than the healthy subset. Figure 2 
represents these findings. The results indicate that, when given in combination with 3NP, Sim 
and the higher dose of ZolA are highly toxic, especially when given together. One anomaly is 
that 3NP-Sim was not toxic when combined with the lower dose of ZolA.  
 Figure 2.  Animal health as a function of drug treatment. 
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Table 2 
Mean Scores and Differences Across Health as a Function of Drug Treatment  
 
 
Sal/Sal1 
N = 11 
3NP/Sal2 
N = 19 
3NP/Sim 
N = 12 
3NP/1Zol3 
N = 12 
3NP/Sim+1Zol4 
N = 12 
3NP/Sim+.5Zol5 
N = 9 
Sal/Sim+.5Zol6 
N = 6 
F 
 Means (SD)  
Health 1.00 (.00)1234 1.68 (.82)1246 1.92 (.90) 2.67 (.79)1356 2.83 (.39)12456 1.22 (.67)345 1.00 (.00)2346 13.492* 
Note: Like superscripts indicate significant differences on post-hoc contrasts, Dunnett C (p < .05).  * = p < .001 
 
 
Table 3 
Summary of Regression Analysis: Drug Treatment Predicting Health 
R2 Adjusted 
R2 
Std. Error of the 
Estimate 
Change Statistics 
 
 
 R2 Change F Change df1 df2 Sig. F Change 
0.51 0.49 0.66 0.51 20.12 4 76 .000 
Predictors: 3NP, Sim, 1ZolA, 0.5ZolA 
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Table 4 
Summary of Regression Analysis: Drug Treatments Predicting Health 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. Correlations 
 B Std. 
Error 
Beta   Zero-order Partial Part 
(Constant) 3.568 .574  6.216 .000    
3NP -.541 .200 -.239 -2.710 .008 -.469 -.297 -.217 
Sim -.236 .179 -.128 -1.319 .191 -.061 -.150 -.105 
1 ZolA -.986 .179 -.488 -5.506 .000 -.641 -.534 -.440 
0.5 ZolA .532 .242 .224 2.197 .031 .365 .244 .176 
Dependent Variable: Health 
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T-Maze 
Data were analyzed using a multivariate analysis of variance (MANOVA) in order to test 
the hypothesis that Time to Complete the task and Task Performance (the dependent variables) 
differed as a function of Drug Treatment group (independent variables: Drug Treatment) while 
controlling for the influence of Number of treatment Injections (covariate). 
There was no sign of existing outliers or abnormalities in kurtosis and skew. Further, 
scatter plot and Pearson correlations suggested that Time to Complete the task and Task 
Performance (dependent variables) as well as Number of Injections (covariate) were linearly 
related (p < .05), but not to a strong degree (i.e. multicolinearity should not be an issue of 
concern, r < .65); thus, assumptions of normality and linearity posed no threat to MANOVA 
interpretation. Due to the high degree of association between the dependent variables (r > .65), 
we interpreted univariate results with caution. Box’s M test was not significant (p = .058), thus 
Wilks’ Lambda criterion was used to determine multivariate main effects of the independent 
variable and its interaction with the covariate. The non-significant Levene’s tests for both Time 
to Complete the task (p = .666) and Task Performance (p = .321) allowed us to assume 
homogeneity of variance. As recommended by Tabachnick and Fidell (2001), homogeneity of 
regression was tested by creating and examining an interaction term between the Number of 
Injections and Drug Treatment group in relation to Performance on the T-maze. Because the 
interaction was non-significant (p = .264), we could assume homogeneity of regression.   
  After adjusting for Number of treatment Injections, results of the MANOVA suggested 
that Drug Treatment group did not have a significant multivariate effect [F(10, 68) = 1.429, p = 
.187, η2 = .174, Wilks’ Lambda = .683] on corrected Time to Complete task and corrected Task 
Performance. Univariate analyses of variance (ANOVA’s) showed no differences in Task 
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Performance amongst different Drug Treatment groups when controlling for Number of 
Injections [F(5, 35) = 1.401, p = .248, η2 = .167]; however, Time to Complete the task varied 
between Drug Treatment groups when controlling for Number of Injections [F(5, 35) = 2.946, p 
< .05, η2 = .296]. These results show the strength of the relationship between adjusted Time to 
Complete the task and Drug Treatment groups was η2 = .296, or in other words, 29.6% of the 
variance in the amount of Time to Complete the task was predicted by Drug Treatment groups 
when controlling for Number of treatment Injections. To account for type 1 error, LSD post-hoc 
tests were conducted to see where differences between Drug Treatment groups may have existed. 
Table 5 summarizes the estimated means, standard deviations, and sample size (n) for each group 
when controlling for Number of treatment Injections.  
 When controlling for Number of Injections, we can conclude that subjects in the 
3NP/Sim treatment group performed significantly worse on the T-maze than the Sal/Sal 
treatment group while needing significantly more Time to Complete the task than the Sal/Sal, 
3NP/Sim+.5Zol, and Sal/Sim+.5Zol treatment groups. These findings do not support our main 
hypothesis that the biggest difference would be between the animals in the Sal/Sal and 3NP/Sal 
treatment groups. 
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Table 5 
Mean Scores and Differences Across the Measures in the T-Maze  as a Function of Drug Treatment when Controlling for Number 
of Injections 
 Sal/Sal 
N = 11 
3NP/Sal 
N = 10 
3NP/Sim 
N = 5 
3NP/1Zol 
N = 2 
3NP/Sim+.5Zol 
N = 8 
Sal/Sim+.5Zol 
N = 6 
F 
Means (SD) 
Performance 72.2 (17.66)1 64 (20.11) 49 (27.02)1 87.5 (10.61) 74.37 (23.97) 79.17 (21.54) 1.401 
Completion Time 3.24 (1.73)1 3.73 (1.15) 5.43 (1.88)1 2.63 (.51) 2.89 (1.16)1 2.28 (1.02)1 2.946* 
Note: Like superscripts indicate significant differences on post-hoc contrasts, LSD (p < .05).  * = p < .05 
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Morris Water Maze 
Originally data were analyzed with analyses of covariance (ANCOVA) in order to test 
the hypothesis that Performance (dependent variable) differed as a function of Drug Treatment 
group (independent variables: Table 1) when controlling for the influence of Number of 
treatment Injections (covariate). Scatter plot and Pearson correlation suggested that Performance 
(dependent variable) and Number of Injections (covariate) were not linearly related (p = .453); 
therefore, we decided to conduct a one way analysis of variance (ANOVA) to test whether 
Performance (dependent variable) on the MWM varies amongst Drug Treatment groups 
(independent variable).  
There was no sign of existing outliers or abnormalities in kurtosis and skew. Levene’s 
test was non-significant (p = .065), thus we could assume homogeneity of variance. Results 
indicated no significant differences in Performance existed amongst the different Drug 
Treatment groups: F(4, 41) = .845, p = .506, although all groups improved with trials. Table 6 
presents the means, standard deviations, and sample size (n) for each group.  
 Unlike our prediction regarding the effects of striatal damage on the ability to learn the T-
maze, we did not find evidence that Performance on the hippocampally-mediated spatial task 
was influenced by Drug Treatment or the general Health of the animal, nor was there sufficient 
evidence to suggest the animals learned the task.  
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Table 6 
Mean Scores and Standard Deviations Across Performance on the MWM  as a Function of Drug 
Treatment 
 Sal/Sal 
N = 11 
3NP/Sal 
N = 12 
3NP/Sim 
N = 5 
3NP/Sim+.5Zol 
N = 8 
Sal/Sim+.5Zol 
N = 6 
F 
 Means (SD) 
Performance 60.71 
(11.85) 
58.18 
(19.27) 
49.64 
(8.87) 
61.61 (12.77) 64.29 (11.52) .845 
Note: Like superscripts indicate significant differences on post-hoc contrasts, LSD (p < .05) 
 
Discussion 
In this study, we used a mouse model of selective striatal damage by 3NP administration 
to mimic symptoms presented in the genetic disorder, Huntington’s disease. We hypothesized 
that drug treatments targeting the farnesylation of Rhes would alleviate striatally- and 
hippocampally-mediated cognitive decline induced by the damaging effects of 3NP and 
measured by subjects’ performance in shallow water variants of a T-Maze and MWM. Overall, 
we failed to reject the null hypothesis that mice administered 3NP would perform worse than 
control mice on cognitive measures. In addition, we could not reliably interpret whether drug 
treatments would prevent prenylation of Rhes and alleviate the hypothesized cognitive decline 
induced by 3NP administration. Further complicating our measures, we did not anticipate the 
drugs’ severely toxic side effects.   
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Animal health and drug toxicity   
Throughout this experiment, our sample size drastically dropped from 82 subjects to 42. 
In attempting to identify which factors were having adverse, toxic effects, the following patterns 
emerged. Animals treated with ZolA at 0.5 mg/kg did not display any toxic or adverse side 
effects compared to Sal-treated animals. By contrast, when the dose of ZolA was increased to 1 
mg/kg and given in combination with 3NP, animals were the sickest and had the highest 
mortality rate. (ZolA at 1 mg/kg was not given in the absence of 3NP). Thus, in general, two 
health groups can be discerned based on whether and how much ZolA was given (0-0.5 mg/kg = 
good health; 1 mg/kg [+ 3NP] = poor health). 3NP alone had an adverse effect on health as 
indicated by the fact the health of mice given this treatment alone was in between that of the 
healthy mice and the sickest mice. The presence or absence of Sim does not alter these 
categorizations (based on homogenous subsets of non-significant differences between group 
means). 
The cumulative dose of 3NP (560 mg/kg) had highly variable results on animal welfare 
during both our pilot study and main experiment. Stefanova et al. (2005) describe the behavioral 
effects in both a low dose (430 mg/kg) and a high dose (560 mg/kg) of sub-chronic 3NP 
treatment on mice – neither of which resulted in death prior to sacrifice. Nearly half of the low 
dose group never developed motor impairment, thus we opted to use the high dose. These results 
were consistent to those found in our pilot data of both treatment regimens, and no deaths were 
recorded. Yet in our main experiment, of the initial set of twelve 3NP/Sal treated mice, four died 
before we could test them for behavior and five were too sick to perform. Because our sample 
size was therefore too low to analyze reliably, we added another seven animals to this treatment 
group; none of these additional animals died or were too sickly to perform prior to testing day. It 
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is possible that this variability in 3NP-induced toxicity was present in groups that received 
additional, ameliorative drugs, thereby reducing our power to detect significant effects of these 
drugs. Every attempt to minimize animal suffering was made; however, in some instances death 
came suddenly, making euthanasia impossible.   
Zoledronic acid at the dose of 1 mg/kg was additionally highly toxic compared to its 0.5 
mg/kg counterparts. According to Pfizer’s Material Safety Data Sheet (2010), the minimal lethal 
intravenous (I.V.) dose for mice is >10 mg/kg. Because drugs are more quickly absorbed into the 
bloodstream via I.V. administration, one would think that our dosage of 1 mg/kg 
intraperitoneally (I.P.) over six days would be a safer option. Though several studies have used 
this drug subcutaneously, intravenously, and intraperitoneally at lower doses (Green and Lipton, 
2010), we decided to take the risk to ensure the drug would be effective at crossing the BBB. 
This was a bold, but informative move. Kuiper et al. (2011) however found that ZolA 
administered at 2 µg/kg in mice adversely suppressed neutrophil activity in a dose-dependent 
manner which led to cell death and subsequent impaired immune system. Alternatively, the 
ED50 of ZolA subcutaneously administered was determined at a dose of 0.07 mg/kg (Widler et 
al., 2002). Because survivability of the 0.5 ZolA administered mice was drastically different than 
that of the 1 ZolA group, we can conclude that ZolA was toxic at higher doses. This, however, 
also could have been exacerbated by the differential toxicity in 3NP administration that we 
observed.  
The results indicated that Sim was part of the intermediate sickly group. There is not 
extensive data to support the toxicity of Sim in animals; however, the Cayman Chemical 
Company’s Material Safety Data Sheet (2010) indicates intraperitoneal LD50 in the rat to be 705 
mg/kg – a value much higher than our 40 mg/kg administered. This finding was similar to that of 
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the 3NP/Sal treated animals, so we may be able to conclude that toxic effects were induced by 
the selective striatal neurotoxin.   
Behavioral Performance  
In regards to our first hypothesis, we did not obtain sufficient evidence to reject the null 
hypothesis. Results indicated that striatally- and hippocampally-mediated cognitive impairments 
associated with Huntinton’s disease were not consistent with our 3NP animal model. This was 
exemplified in both performance of mice in the shallow water variants of the T-maze and MWM.  
Results showed that performance on the T-maze did not differ as a function of drug 
treatment administration when controlling for number of treatment injections received. Likewise, 
results indicated that drug treatment administration did not alter performance on the shallow 
water variant of the MWM. Overall, these were inconsistent with our hypotheses and the 
literature that the lesioning effects of 3NP in the striatum and hippocampus would lead to 
striatally- and hippocampally-mediated cognitive decline as evidenced by performance in the T-
maze and MWM.  
Our current study lacks the histological data necessary to determine definitively whether 
or not our 3NP dosage regimen did in fact produce lesions similar to those seen in other studies 
(high-dose, sub-chronic treatment). Colleagues Whitmarsh and LaHoste (paper currently in 
progress), however, showed 3NP/Sal treated animals performed significantly worse on the 
rotarod (a common measure of striatal integrity) than control animals. Our cumulative treatment 
of 3NP may have been too high, mimicking the hypokinetic effects commonly seen in sub-
chronic and chronic dosing regimens (Tunez, Tasset, De La Cruz, and Santamaria, 2010). While 
the rotarod data could point to support of striatal neuronal degeneration, it could also be the mark 
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of impairment in motor behavior due to adverse effects of the drug treatments. This conclusion is 
additionally plausible due to the severely compromised health of the animals.  
Results vary in support of either of these theories because 3NP/Sim treated animals, in 
comparison to healthy controls, needed significantly more time to complete the T-maze and 
performed worse; however, they did not differ in either regard to animals in the 3NP/Sal, or any 
other, treatment group. Furthermore, performance on the MWM did not differ between mice in 
any of the treatment groups. We are forced to retain the second null hypothesis that drug 
treatment inhibiting the prenylation of Rhes would alleviate adverse cognitive symptoms caused 
by 3NP because there were no significant differences between performance and any of the drug 
treatments involving 3NP. Because we failed to reject the first null hypothesis, we cannot 
reliably conclude whether or not Sim or ZolA treatments were effective in disrupting the 
mevalonate pathway to lead to an absence of Rhes and retardation of cognitive impairment.  
It is possible that we did in fact achieve striatal and hippocampal lesions, but one could 
question whether or not our cognitive tasks were appropriate to test them. In both water and 
land-based learning mazes, rodents with lesions to the CPu fail to learn egocentric, procedural-
type learning and rather employ alternative strategies that are more allocentric or spatial-like 
while rodents with lesions to the hippocampus will fail to learn allocentrically and rather utilize 
egocentric strategies (Devan, Goad, and Petri, 1996; Oliveira, Bueno, Pomarico, and Gugliano, 
1997; and Pistel et al., 2009). Results, however, indicated that learning did in fact occur across 
treatment groups in both the T-Maze and MWM. The methodology used in our T-maze was 
sound to test for egocentric learning. The lack of differences in performance between groups of 
mice may have then been caused by the short time frame mice were allowed to learn the task, the 
timing of task conductance within drug treatment regimen, the lack of lesion to the striatum, or a 
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need to increase the number of animals in each group. Because of positive rotatod data from our 
colleagues, we strongly believe a lesion to have existed. Due to positive scores across all 
treatment groups, however, we believe our methodology on trial periods and timing in task 
administration was appropriate, and we more than likely needed to increase the number of 
animals in each treatment group. This is especially true considering the vast differences in health 
between our first group of 3NP/Sal treated animals and our second. The methodology in our 
shallow water variant of the MWM was a bit more questionable given the results. We did not 
have a tracking system to include further measures, so the amount of data collected for analysis 
was minimal. Patterned cue cards attached to the walls could have acted as both spatial 
references (spatial-hippocampal based) or as visual discriminants (procedural-striatal based). 
Depending on where lesions existed, it is difficult to predict performance on this task. Saline 
control mice could have employed either learning strategy, making comparisons to other groups 
difficult. While the literature supports that 3NP-induced hippocampal lesions do not occur 
without the presence of striatal lesions, we may be able to conclude that 3NP treated mice were 
more likely to employ their spatial, cue-based strategies to navigate the maze because it was 
likely that neurons in the striatum were more compromised than those in the hippocampus. Even 
if this is the case, however, the lack of differences in performance across the groups treated with 
3NP clearly indicated treatment drugs had no effect. It may be the case that differences in 
cognition did not exist, or that our task needed more training periods or increases in subject 
number.   
Brouillet, Jacquard, Bizat, and Blum (2005) wrote an extensive review on the 
mechanisms behind 3NP, and we may not have seen differences in performance across treated 
mice because of them. There are vast toxicity differences between mice and rats, with rats 
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reacting more adversely to 3NP I.P. injection; and there are further differences within each 
different strain of rodent. Age is a significant factor as older mice are more susceptible to 
damage, and males are more affected than females. While we did use the more fragile male 
rodents, they could have also been more protected from neuronal damage because they were 
mice and they were relatively young, ~2 months old. This could explain in part the differences 
between our study and the findings in the literature exemplifying deficits in performance on 
striatally- and hippocampally-mediated cognitive tasks. The methodology and number of animals 
used could have been appropriate, with only nature exerting its protective effect.  
Whether or not the lack of significant differences in performance on both tasks was due 
to an absent lesion, inappropriate methods, small sample size, inappropriate timing of task 
administration, natural protectants, or legitimate neurological outcomes, results showed that 
there were no differences in performance on cognitive tasks between 3NP treated mice and 
controls. The sub-chronic dosing of 3NP at 560 mg/kg over 7 days did not produce deficits in 
cognition, and thus we were unable to test whether or not drug treatment blocking the 
mevalonate pathway would exert alleviation of the non-existing symptomology. 
Future Directions 
The central goal of this thesis was to elucidate cognitive dysfunction in a 3NP mouse 
model of HD and ameliorate abnormalities by inhibiting Rhes prenylation through drug 
treatments targeting the mevalonate pathway. In understanding how certain molecular pathways 
are involved with neurodegeneration caused by either genetic means or neurotoxin, we can 
further aim to find treatments that target them and improve subsequent behavior abnormalities. 
The implications of studying such models could lead to further treatment applications to diseases 
that follow the same patterns of neurodegeneration or include the mavelonate pathway. The 
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mavelonate pathway is a ubiquitous biochemical sequence in cellular signaling.  Perhaps the 
effects of our drugs on system organs obscured any effect in the brain.  We were restricted to the 
use of drugs that crossed the blood-brain-barrier (BBB; either alone or following 3NP) and to 
drugs that could be obtained feasibly.  Future experiments could employ intracerbral 
administration of potentially ameliorative drugs, thereby by-passing their natural ability to cross 
the BBB and would require much less drug, thereby allowing the use of otherwise financially 
prohibitive drugs. 
Our study was unique and relied on previously published data for the establishment of 
experimental parameters.  Furthermore, although we controlled for potentially confounding 
variables, we did not anticipate the degree of variability that we observed. Although we did 
conduct pilot studies, we could have conducted more provided we were given the time to do so. 
Future work needs to be done to increase the literature on several aspects. There need to be more 
defined 3NP dosage regimens for acute, sub-chronic, and chronic conditions in addition to a 
more cohesive review clarifying differences in dose between rodent species. Cognitive and 
motor behavior needs to be analyzed based on these data and methodology replicated to unify the 
deviation from normalcy with the lesioning literature. Further applications to the field would be 
related to the research on inhibition of enzymatic tartgets in the malevolent pathway leading to 
prenylation of Rhes and thus retardation of motor or cognitive abnormalities. Clearly the 
literature is vastly lacking cohesive knowledge in several aspects specific to the selective striatal 
neuronal degeneration induced by 3NP treatment. Without conducting studies with more reliable 
methodology, we may never have the literature support we need to generate valid conclusions.  
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